NasdaqCM - Nasdaq Real Time Price USD

Psyence Biomedical Ltd. (PBM)

4.2750

-0.1650

(-3.72%)

At close: May 7 at 4:00:00 PM EDT

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

New York, New York--(Newsfile Corp. - May 1, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the effective date of its 1-for-7.97 share consolidation (reverse stock split) of the Company's issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a share consolidation at a ratio of up to 1-for-50. Following this approval, the Company's Board of Directors authorized a ...

Newsfile 6 days ago

PBM
-3.72%

PBMWW
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") announced today that it received a notification letter dated April 16, 2025, from the Listings Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the ...

Newsfile 20 days ago

PBM
-3.72%

PBMWW
Psyence Group Announces Share Consolidation

TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share capital (the "Common Shares") on the basis of every fifteen (15) old Common Shares into one (1) new Common Share (the "Share Consolidation"), effective April 23, 2025 with a record date of April 23, 2025 (the "Record Date"). As a result of the Share Consolidation, the issued and outstanding Common S

GlobeNewswire 20 days ago

PSYGF

PBM
-3.72%

PBMWW
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, and drug development. This follow-on investment underscores Psyence BioMed's commitment to building a vertically integrated, multi-asse

Newsfile 22 days ago

PBM
-3.72%

PBMWW
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

New partnership strengthens Psyence BioMed's global clinical trial capabilities, accelerating the development of psilocybin-assisted therapy for adjustment disorder New York, New York--(Newsfile Corp. - April 8, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the signing of a Letter of Intent (LOI) with Southern Star Research Pty Ltd, a premier Australian contract research organization (CRO). This collaboration will accelerate Psyence BioMed's ongoing Pha

Newsfile 29 days ago

PBM
-3.72%

PBMWW
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025 New York, New York--(Newsfile Corp. - March 31, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") releases the following update:Dear Shareholders and Future Investors:At Psyence BioMed, we are truly grateful for the ongoing support and trust of our shareholders. Your dedication to our vision drives our growth, and we're excited to share our latest ...

Newsfile last month

PBM
-3.72%

PBMWW
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it has expanded its newly created Scientific Advisory Board (SAB) with the addition of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology. According to a news release issued by PBM, Dr. Stein is the Professor and Chair of the Dept of Psych

GlobeNewswire last month

PSYGF

PBM
-3.72%

PBMWW
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies New York, New York--(Newsfile Corp. - March 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence Biomed" or the "Company") today announced that it has expanded and further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology. He is the Professor and Chair of the Dept of Psychiatry and ...

Newsfile last month

PBM
-3.72%

PBMWW
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

Psyence Group settles Debt for SharesTORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). According to a news release issued by PBM, Dr. Garcia-Romeu is a leading psychedelics researche

GlobeNewswire last month

PSYGF

PBM
-3.72%

PBMWW
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

Scientific Advisory Board will bring significant expertise in psilocybin research and clinical trial designNEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatr

GlobeNewswire 2 months ago

PBM
-3.72%

PBMWW
Psyence Biomed Announces Closing of $2.0 Million Private Placement

NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrants in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common shar

GlobeNewswire 4 months ago

PBM
-3.72%

PBMWW
Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position

Psyence Biomedical ( (PBM) ) has provided an announcement. Psyence Biomedical Ltd. has regained compliance with all Nasdaq continued listing requirements after transferring from The Nasdaq Global Market to The Nasdaq Capital Market. This was achieved through a 75-for-1 share consolidation, meeting the $1 minimum bid price requirement. With a debt-free balance sheet and $5.6 million in cash, the company is now well-positioned to advance its business plans and clinical trials, having begun patient

TipRanks 4 months ago

PBM
-3.72%

PBMWW
Psyence Biomed Announces $2.0 Million Private Placement

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-fu

GlobeNewswire 4 months ago

PBM
-3.72%

PBMWW
Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheetNEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq continued listing requirements. As previously announced, Psyence Biomed requested to be transferred from The Nasdaq Global Market to The Nasdaq Capi

GlobeNewswire 4 months ago

PBM
-3.72%

PBMWW
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO), Australian Clinical Trial Network (ACTioN), has been engaged to implement patient recruitment and retention strategies NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today highlighted recent progress that has been made with its active Phase IIb clinical trial of nature deri

GlobeNewswire 4 months ago

PBM
-3.72%

PBMWW
Psyence Biomedical executes binding agreements with Optimi Health

Psyence Biomedical (PBM) announced that it has progressed beyond the previously-announced non-binding Letter of Intent, LOI, and executed binding agreements with Optimi Health Corp. Under the terms of the agreements, Optimi becomes the exclusive supplier of GMP-certified, nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved uses in the Palliative Care context. Optimi will provide comprehensive Chemistry, Manufa

TipRanks 4 months ago

PBM
-3.72%

PBMWW
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Biomed obtains exclusive worldwide supply rights to Optimi’s GMP-certified, nature-derived psilocybin for its drug development and commercialization initiatives in Palliative CareNEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced that it has progressed beyond the previously-announced non-binding Letter of Intent (LOI) and executed binding agreements with Optimi Health Corp. Under the terms of the agreement

GlobeNewswire 4 months ago

PBM
-3.72%

PBMWW
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the "Debt Swap Agreements") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 337,750 Psyence Biomed common shares at a deemed price of US$3.88 per common shar

GlobeNewswire 4 months ago

PSYGF

PBM
-3.72%

PBMWW
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Independent valuation of PsyLabs values Psyence Biomed’s stake at approximately $2 million, doubling in value Debt-for-equity swap with Psyence Group and Newcourt SPAC Sponsor results in strengthened balance sheet, with substantially reduced debt, heading into 2025 Psyence Biomed believes it is on track to regain compliance with all applicable Nasdaq continued listing requirements by year-end Phase IIb clinical trial progressing as planned; patient screening has commenced NEW YORK, Dec. 03, 2024

GlobeNewswire 5 months ago

PBM
-3.72%

PBMWW
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Agrify secured $25.9 million through non-brokered private placement Cannabis giant StateHouse Holdings’ assets up for sale in record receivership deal Simply Solventless surpassed guidance and reported robust financial growth in Q3 2024 Decibel reported mixed Q3 financial results amid market adjustments Key Takeaways; Psychedelic Sector Psyence Biomedical announced 1-for-75 share consolidation […]

Market Exclusive 5 months ago

AGFY

STHZF

DBCCF

Performance Overview

Return	PBM	S&P 500 (^GSPC)
YTD	-74.67%	-4.26%
1-Year	-99.31%	+8.55%
3-Year	-99.93%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Psyence Biomedical Ltd. (PBM)

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Group Announces Share Consolidation

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position

Psyence Biomed Announces $2.0 Million Private Placement

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Psyence Biomedical executes binding agreements with Optimi Health

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Performance Overview